Stempoint Capital LP 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
Stempoint Capital LP disclosed 75 US equity positions worth $582.7m in its Q4 2025 13F filing. The largest position was ABVX at 9.1% of the reported book, followed by SRRK and CNTA. Against the Q3 2025 filing, it opened 17 new positions, added to 22 and reduced 11 among the top 50 holdings.
What did Stempoint Capital LP own in Q4 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2025 |
|---|---|---|---|---|---|---|---|
| 1 | ABVX ABIVAX SA | 9.1% | $52.8m | 391,783 | 136% | added | |
| 2 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 6.7% | $39.1m | 886,893 | 22% | added |
| 3 | CNTA CENTESSA PHARMACEUTICALS PLC | 5.0% | $28.9m | 1,154,114 | 76% | added | |
| 4 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 4.8% | $28.1m | 1,339,379 | -2% | reduced |
| 5 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 4.2% | $24.4m | 351,073 | 171% | added |
| 6 | ACLXGBX ARCELLX INC | 3.7% | $21.7m | 332,860 | 2826% | added | |
| 7 | ROIV ROIVANT SCIENCES LTD | Healthcare | 3.6% | $21.0m | 966,698 | -77% | reduced |
| 8 | 430 TERNS PHARMACEUTICALS INC | 3.0% | $17.3m | 429,198 | 379% | added | |
| 9 | TWST TWIST BIOSCIENCE CORP | Healthcare | 2.8% | $16.4m | 518,355 | – | new |
| 10 | IMVT IMMUNOVANT INC | Healthcare | 2.8% | $16.4m | 644,959 | -59% | reduced |
| 11 | DYN DYNE THERAPEUTICS INC | Healthcare | 2.8% | $16.3m | 835,200 | 76% | added |
| 12 | XENE XENON PHARMACEUTICALS INC | Healthcare | 2.7% | $15.6m | 348,605 | 81% | added |
| 13 | SRZN SURROZEN INC | 2.2% | $12.7m | 619,766 | -13% | reduced | |
| 14 | CELC CELCUITY INC | Healthcare | 2.0% | $11.8m | 118,333 | -13% | reduced |
| 15 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 1.8% | $10.5m | 290,049 | 83% | added |
| 16 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 1.8% | $10.3m | 17,736 | 116% | added |
| 17 | ADPT ADAPTIVE BIOTECHNOLOGIES COR | Healthcare | 1.7% | $9.9m | 606,825 | – | new |
| 18 | PALI PALISADE BIO INC | Healthcare | 1.7% | $9.9m | 4,192,375 | – | new |
| 19 | CYTK CYTOKINETICS INC | Healthcare | 1.6% | $9.3m | 146,978 | – | new |
| 20 | EWTX EDGEWISE THERAPEUTICS INC | 1.5% | $9.0m | 360,876 | – | new | |
| 21 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 1.3% | $7.6m | 97,340 | – | new |
| 22 | NKTR NEKTAR THERAPEUTICS | Healthcare | 1.3% | $7.5m | 178,274 | 235% | added |
| 23 | JNJ JOHNSON & JOHNSON | Healthcare | 1.2% | $7.2m | 35,000 | – | new |
| 24 | DNLI DENALI THERAPEUTICS INC | Healthcare | 1.2% | $6.9m | 419,058 | -76% | reduced |
| 25 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 1.2% | $6.8m | 565,140 | 104% | added |
| 26 | CLPT CLEARPOINT NEURO INC | 1.1% | $6.6m | 481,858 | 2794% | added | |
| 27 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 1.1% | $6.5m | 224,740 | -45% | reduced |
| 28 | EYPT EYEPOINT INC | Healthcare | 1.1% | $6.5m | 353,849 | – | new |
| 29 | IMTX IMMATICS N.V | Healthcare | 1.1% | $6.4m | 610,308 | – | new |
| 30 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 1.1% | $6.3m | 522,693 | 45% | added |
| 31 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 1.1% | $6.3m | 58,915 | -36% | reduced |
| 32 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 1.1% | $6.2m | 21,067 | – | new |
| 33 | APGE APOGEE THERAPEUTICS INC | Healthcare | 1.0% | $6.1m | 80,574 | – | new |
| 34 | INCY INCYTE CORP | Healthcare | 1.0% | $6.1m | 61,435 | 40% | added |
| 35 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 1.0% | $5.6m | 161,659 | -57% | reduced |
| 36 | ASMB ASSEMBLY BIOSCIENCES INC | Healthcare | 0.9% | $5.3m | 156,728 | 137% | added |
| 37 | MAZE MAZE THERAPEUTICS INC | 0.9% | $5.2m | 125,877 | – | new | |
| 38 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 0.9% | $5.2m | 59,430 | 24% | added |
| 39 | LLY ELI LILLY & CO | Healthcare | 0.9% | $5.1m | 4,759 | – | new |
| 40 | TRVI TREVI THERAPEUTICS INC | Healthcare | 0.9% | $5.0m | 399,557 | 14% | added |
| 41 | RVMD REVOLUTION MEDICINES INC | Healthcare | 0.8% | $4.9m | 62,032 | -67% | reduced |
| 42 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 0.8% | $4.8m | 154,320 | – | new |
| 43 | ABUS ARBUTUS BIOPHARMA CORP | Healthcare | 0.8% | $4.7m | 986,751 | 380% | added |
| 44 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 0.8% | $4.6m | 348,401 | – | new |
| 45 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 0.8% | $4.4m | 1,036,311 | – | new |
| 46 | XFOR X4 PHARMACEUTICALS INC | 0.6% | $3.6m | 898,465 | 62% | added | |
| 47 | WHWK WHITEHAWK THERAPEUTICS INC | Healthcare | 0.6% | $3.5m | 1,458,807 | 244% | added |
| 48 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 0.6% | $3.3m | 79,284 | 92% | added |
| 49 | ASND ASCENDIS PHARMA A/S | Healthcare | 0.5% | $3.2m | 14,842 | -2% | reduced |
| 50 | RGEN REPLIGEN CORP | Healthcare | 0.4% | $2.6m | 15,707 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.